| Dr Michael John Licata, MD | |
|
300 Pinellas St, Clearwater, FL 33756-3804 | |
| (727) 734-6635 | |
| Not Available |
| Full Name | Dr Michael John Licata |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 20 Years |
| Location | 300 Pinellas St, Clearwater, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780664961 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Morton Plant Mease Healthcare Countryside | Safety harbor, FL | Hospital |
| Morton Plant Hospital | Clearwater, FL | Hospital |
| Mease Dunedin Hospital | Dunedin, FL | Hospital |
| Morton Plant North Bay Hospital | New port richey, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clearwater Pathology Associates | 9931131513 | 9 |
News Archive
New study findings showcased at the 13th European Cancer Conference (ECCO) have shed further light on the manifold factors which must be considered when managing patients with cancer. Studies from around Europe looked at a number of the issues faced by cancer patients and assessed their impact and associated implications.
A comprehensive study done by the Georgia Institute of Technology shows the built environment clearly relates to a person's prospects for being overweight. Every additional 30 minutes a person spends in a car translates into a 3 percent greater chance of being obese.
A phase 2 trial just concluded shows that people with celiac disease may now be able to hope for a cure, through a treatment that makes the immune system tolerant towards gluten. This could eventually make it possible for such individuals to eat gluten-containing foods without fear.
Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.
› Verified 4 days ago
| Entity Name | Mease Pathology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730240995 PECOS PAC ID: 3173425089 Enrollment ID: O20040122000189 |
News Archive
New study findings showcased at the 13th European Cancer Conference (ECCO) have shed further light on the manifold factors which must be considered when managing patients with cancer. Studies from around Europe looked at a number of the issues faced by cancer patients and assessed their impact and associated implications.
A comprehensive study done by the Georgia Institute of Technology shows the built environment clearly relates to a person's prospects for being overweight. Every additional 30 minutes a person spends in a car translates into a 3 percent greater chance of being obese.
A phase 2 trial just concluded shows that people with celiac disease may now be able to hope for a cure, through a treatment that makes the immune system tolerant towards gluten. This could eventually make it possible for such individuals to eat gluten-containing foods without fear.
Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.
› Verified 4 days ago
| Entity Name | Clearwater Pathology Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629138250 PECOS PAC ID: 9931131513 Enrollment ID: O20050902000601 |
News Archive
New study findings showcased at the 13th European Cancer Conference (ECCO) have shed further light on the manifold factors which must be considered when managing patients with cancer. Studies from around Europe looked at a number of the issues faced by cancer patients and assessed their impact and associated implications.
A comprehensive study done by the Georgia Institute of Technology shows the built environment clearly relates to a person's prospects for being overweight. Every additional 30 minutes a person spends in a car translates into a 3 percent greater chance of being obese.
A phase 2 trial just concluded shows that people with celiac disease may now be able to hope for a cure, through a treatment that makes the immune system tolerant towards gluten. This could eventually make it possible for such individuals to eat gluten-containing foods without fear.
Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael John Licata, MD 300 Pinellas St, Clearwater, FL 33756-3804 Ph: (727) 462-7062 | Dr Michael John Licata, MD 300 Pinellas St, Clearwater, FL 33756-3804 Ph: (727) 734-6635 |
News Archive
New study findings showcased at the 13th European Cancer Conference (ECCO) have shed further light on the manifold factors which must be considered when managing patients with cancer. Studies from around Europe looked at a number of the issues faced by cancer patients and assessed their impact and associated implications.
A comprehensive study done by the Georgia Institute of Technology shows the built environment clearly relates to a person's prospects for being overweight. Every additional 30 minutes a person spends in a car translates into a 3 percent greater chance of being obese.
A phase 2 trial just concluded shows that people with celiac disease may now be able to hope for a cure, through a treatment that makes the immune system tolerant towards gluten. This could eventually make it possible for such individuals to eat gluten-containing foods without fear.
Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.
› Verified 4 days ago
Antonela C Zanchi, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 300 Pinellas St, Ms-32, Clearwater, FL 33756 Phone: 727-462-7062 | |
Ronald R Willey, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1927 Cove Lane, Clearwater, FL 33764 Phone: 727-536-0687 | |
Robert S Shibata, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 300 Pinellas St, Clearwater, FL 33756 Phone: 727-462-7000 | |
Dr. Nicholas Lancia, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2631 Mccormick Dr Ste 101, Clearwater, FL 33759 Phone: 727-842-4848 Fax: 727-842-9513 | |
George D Schaefer, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 300 Pinellas St, Ms-32, Clearwater, FL 33756 Phone: 727-462-7062 | |
Dr. Kimiko Takezawa, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 13770 58th St N, Suite 309, Clearwater, FL 33760 Phone: 727-539-1395 Fax: 727-539-1397 |